Experienced CFO joins clinical-stage biopharmaceutical company

  • Esther Rajavelu named chief financial and business officer of Spero Therapeutics
  • Rajavelu previously served as CFO of Fulcrum Therapeutics
  • Annual base salary of $475,000 and target annual bonus of 40% of base pay
  • Stephen DiPalma has been interim CFO since August 1

Spero Therapeutics has announced the appointment of Esther Rajavelu as its new chief financial and business officer. Rajavelu, who previously served as the CFO of Fulcrum Therapeutics, brings a wealth of experience to her new role. She will receive an annual base salary of $475,000 and will have a target annual bonus of 40% of her base pay. Stephen DiPalma has been serving as the interim CFO since August 1, following the promotion of Satyavrat Shukla to president and CEO.

Factuality Level: 10
Factuality Justification: The article provides factual information about the appointment of Esther Rajavelu as the chief financial and business officer of Spero Therapeutics. It includes details about her previous role and the salary she will receive. There is no irrelevant or misleading information, sensationalism, redundancy, or opinion masquerading as fact in the article.
Noise Level: 3
Noise Justification: The article provides straightforward information about the appointment of Esther Rajavelu as the chief financial and business officer of Spero Therapeutics. It includes details about her previous role and the salary she will receive. However, it lacks any analysis, evidence, or insights beyond the basic facts, making it a relatively low-noise article.
Financial Relevance: Yes
Financial Markets Impacted: No
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: This news article pertains to the appointment of Esther Rajavelu as the chief financial and business officer of Spero Therapeutics, a clinical-stage biopharmaceutical company. It does not mention any extreme events or financial market impacts.
Public Companies: Spero Therapeutics (null), Fulcrum Therapeutics (null)
Key People: Esther Rajavelu (Chief Financial and Business Officer), Stephen DiPalma (Managing Director at Danforth Advisors), Satyavrat Shukla (President and Chief Executive)

Reported publicly: www.marketwatch.com